Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:8541
Name Sezary's disease
Definition
Source DiseaseOntology.org
Alt Ids DOID:8790
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Sezary's disease

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01871727 Phase III E7777 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Completed USA | AUS 1
NCT02542124 Phase II Interleukin-12 NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) Unknown status USA 0
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Completed USA | ITA | GBR | FRA | ESP | CAN 0
NCT02616965 Phase I Brentuximab vedotin + Romidepsin A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Active, not recruiting USA 0
NCT02953301 Phase II Resminostat Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN) Completed POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BEL | AUT 1
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03011814 Phase Ib/II Durvalumab Durvalumab + Lenalidomide Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Active, not recruiting USA 0
NCT03063632 Phase II Interferon gamma + Pembrolizumab Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Completed USA 0
NCT03081910 Phase I CD5 CAR-T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03385226 Phase II Pembrolizumab A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) Active, not recruiting GBR 0
NCT03587844 Phase II Brentuximab vedotin Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients Recruiting USA 0
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting USA 0
NCT03695471 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Active, not recruiting USA 0
NCT03902184 Phase II Gemcitabine + Lacutamab + Oxaliplatin Lacutamab IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Active, not recruiting USA | POL | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04185220 Phase I Mogamulizumab + rhIL-15 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed USA 0
NCT04217317 Phase II Bendamustine + CPI-613 CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Terminated USA 0
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04256018 Phase II Mogamulizumab Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sezary Syndrome Recruiting USA 0
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | NOR | ESP | CZE 1
NCT04541017 Phase Ib/II Hu5F9-G4 Hu5F9-G4 + Mogamulizumab Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Terminated USA 0
NCT04652960 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Recruiting USA 0
NCT04676087 Phase Ib/II Mogamulizumab Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Terminated USA 0
NCT04745234 Phase II Mogamulizumab Mogamulizumab Q4week Dosing in Participants With R/R CTCL Active, not recruiting USA | ITA | GBR | FRA | ESP 0
NCT04752826 Phase Ib/II BI-1808 + Pembrolizumab BI-1808 BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) Recruiting USA | SWE | HUN | GBR | DNK 1
NCT04930653 Phase II Mogamulizumab Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Recruiting USA 0
NCT04960618 Phase II Gemcitabine + Pembrolizumab Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sezary Syndrome Recruiting USA 0
NCT05079282 Phase I ONO-4685 Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma Recruiting USA 0
NCT05377827 Phase I WU-CART-007 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Active, not recruiting USA 0
NCT05414500 Phase I Brentuximab vedotin + Mogamulizumab Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Recruiting USA 0
NCT05944562 Phase I Tulmimetostat Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sezary Syndrome Recruiting USA 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT06492304 Phase Ib/II CTX131 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies Recruiting USA 0